Special Report: Platform Drugs—Opportunities in the Market... - Pharmaceutical Executive

ADVERTISEMENT

Special Report: Platform Drugs—Opportunities in the Market...


Pharmaceutical Executive


Create (Smart) Molecules

As early as one year after the launch of the anti-epilepsy treatment Neurontin (gabapentin), small investigator-led clinical studies suggested that GABA agonists—and Neurontin in particular—offer benefits for patients suffering from various types of neuropathic pain. Monitoring off-label prescriptions of Neurontin revealed extensive prescribing for these conditions, with physicians writing an estimated 86 percent of all Neurontin scrips off-label.

Pfizer used this information to create and mitigate the regulatory risk for its follow-on product Lyrica. Pfizer chose to focus on the safer regulatory path—gaining an indication for epilepsy—since it already had a wealth of clinical data from Neurontin. However, the company also set out to prove Lyrica's effectiveness for painful diabetic neuropathy, for which received approval in 2004.

This strategy helped not only mitigated the regulatory risk, but also maximized sales. Generic gabapentin manufacturers could not afford to bankroll trials for neuropathic pain, which isolated Lyrica from third party reimbursement pressure, despite its higher price. As a consequence, Lyrica sales reached $1.2 billion in 2006, and grew to $1.8 billion in 2007. More recently, the company has taken this approach a step further by obtaining a label for fibromyalgia, another indication where Neurontin data was suggestive of efficacy.

Prove Class Effects

Sometimes, even without a reformulation, establishing efficacy in what is perceived to be a class effect can create tremendous value. Companies can use this strategy even when they haven't had a significant presence in the past in a particular franchise area.

For example, in 1998 King Pharmaceuticals acquired the rights to the ACE inhibitor Altace (ramipril)—back then considered a "me-too" drug, with only 4 percent of sales within the class. At the time, many hypothesized that ACE inhibitors had cardio-protective effects beyond blood pressure control, but no one had done the clinical trials to prove it. King took on the challenge: it designed and undertook the landmark Heart Outcomes Prevention Evaluation (HOPE) trial. With that data, FDA approved Altace for prevention of myocardial infarction, stroke, and death due to cardiovascular causes, and the company parlayed this expanded label into a 15 percent class share by 2004.


ADVERTISEMENT

blog comments powered by Disqus
UPCOMING CONFERENCES

Serialization Summit
San Diego, CA
Feb. 27-28, 2014



Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014



ClinTech 2014
Cambridge, MA
Mar. 11-13 2014


Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here